- Home
- KSS vs GPCR Comparison
KSS vs GPCR Comparison
Compare KSS & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- GPCR
- Stock Information
- Founded
- KSS 1962
- GPCR 2016
- Country
- KSS United States
- GPCR United States
- Employees
- KSS N/A
- GPCR N/A
- Industry
- KSS Department/Specialty Retail Stores
- GPCR
- Sector
- KSS Consumer Discretionary
- GPCR
- Exchange
- KSS Nasdaq
- GPCR Nasdaq
- Market Cap
- KSS 2.1B
- GPCR 1.8B
- IPO Year
- KSS 1992
- GPCR 2023
- Fundamental
- Price
- KSS $18.02
- GPCR $34.17
- Analyst Decision
- KSS Hold
- GPCR Buy
- Analyst Count
- KSS 8
- GPCR 5
- Target Price
- KSS $21.38
- GPCR $86.80
- AVG Volume (30 Days)
- KSS 6.5M
- GPCR 677.5K
- Earning Date
- KSS 11-26-2024
- GPCR 11-13-2024
- Dividend Yield
- KSS 11.11%
- GPCR N/A
- EPS Growth
- KSS N/A
- GPCR N/A
- EPS
- KSS 2.54
- GPCR N/A
- Revenue
- KSS $17,124,000,000.00
- GPCR N/A
- Revenue This Year
- KSS N/A
- GPCR N/A
- Revenue Next Year
- KSS N/A
- GPCR N/A
- P/E Ratio
- KSS $7.08
- GPCR N/A
- Revenue Growth
- KSS N/A
- GPCR N/A
- 52 Week Low
- KSS $17.41
- GPCR $26.61
- 52 Week High
- KSS $29.60
- GPCR $66.38
- Technical
- Relative Strength Index (RSI)
- KSS 43.89
- GPCR 35.81
- Support Level
- KSS $18.02
- GPCR $33.85
- Resistance Level
- KSS $18.73
- GPCR $38.48
- Average True Range (ATR)
- KSS 0.73
- GPCR 2.62
- MACD
- KSS 0.00
- GPCR -0.36
- Stochastic Oscillator
- KSS 31.28
- GPCR 3.67
About KSS Kohl's Corporation
Kohl's operates about 1,176 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 26% of its 2023 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.